| |
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
Today’s Big NewsJul 9, 2025 |
|
A pipeline-supporting marketing plan that includes proven tools, well-executed tactics, and a clear strategy are key to keeping your pipeline full of qualified leads. Access this valuable resource to discover how your marketing team can support your business development team in three essential areas: audience, storytelling, and performance. Download today! 
|
|
| By Kevin Dunleavy Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion for Verona Pharma and its potential blockbuster Ohtuvayre, a first-in-class treatment for chronic obstructive pulmonary disorder (COPD). |
|
|
|
By James Waldron AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus capsids from existing partner JCR Pharmaceuticals to develop genomic medicines. |
By Conor Hale The Fierce 15 winner aims to tap into some of the most common procedures performed today—about 200 million per year—with a new category of robotics. |
By Andrea Park Amgen's “The Making of a Heart Attack” film premiered last month on A&E, was featured at the Cannes Lions International Festival of Creativity shortly after and is now available to watch on Amgen’s “Attack Heart Disease” website. |
|
MedTech companies often launch groundbreaking devices, only to face slow adoption due to costly, time-intensive, and difficult-to-scale training. This whitepaper explores how Virtual Reality (VR) is changing that, helping teams engage physicians earlier, accelerate product adoption, and drive stronger commercial outcomes. Download now to learn more. 
|
|
By Nick Paul Taylor Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. A phase 2 trial of the biotech’s next-generation oral candidate hit its primary endpoint, sending the stock up 26%. |
By Angus Liu The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a new dosing regimen of the drug with an improved safety profile. |
By Darren Incorvaia Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. Peter, M.D., and Luke Evnin, Ph.D., launched Vie Ventures on July 9 with the intent to direct funds to biotechs during the series B and C stages. |
By Angus Liu President Donald Trump has renewed his pledge of drug tariffs to the tune of 200%, but with a grace period of around one year. |
By Conor Hale The company said its pilot program completed its first patient procedure that delivered the hypertension therapy to the renal arteries as well as the vessels feeding the liver. |
By Gabrielle Masson Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain barrier crossing technology after a trial period. |
By Fraiser Kansteiner Novo Nordisk has inked a deal with the Tianjin Economic and Technological Development Area to invest roughly $112 million in an upgrade to the quality testing laboratory at its Tianjin, China, manufacturing facility, which has been in operation since 1994. |
By Zoey Becker Iambic will train its AI models with Revolution's collection of proprietary data to pinpoint potential new oncology targets. The deal could yield the AI discovery outfit up to $25 million in upfront and milestone-based payments. |
By Nick Paul Taylor A who’s who of respiratory disease drug developers has backed the American Lung Association’s push to help chronic obstructive pulmonary disease patients in rural communities. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
In all the “what if” chatter and fatigue around AI, predictive sales intelligence is a key opportunity that can easily be implemented and scaled to make omnichannel strategies even more potent. Our whitepaper explores the value of this capability, what role it plays in evolving HCP engagement trends, how to implement, and what to look for when engaging new partners and solutions. Download now.
|
|
Whitepaper This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Sheraton Philadelphia Downtown |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
